Clinical trial NCT05833568: Five-day 20-minute 10-Hz tACS in Patients With a Disorder of Consciousness
Official title: Double-blind Randomized Controlled Trial of a 10-Hz Transcranial Alternating Current Stimulation to Modulate Brain Activity in Brain-injured Patients With Disorders of Consciousness
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Brain Injury Traumatic Severe
Disorder of Consciousness
Brain Injuries
Lead sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Sponsor class: OTHER
Collaborators: name: McGill University Health Centre/Research Institute of the McGill University Health Centre
First posted: 2023-04-27
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study first aims to validate the feasibility of a multimodal 5-day 20-minute tACS protocol in subacute brain-injured patients with a disorder of consciousness during their ICU stay, and conduct a clinical pilot study (validation phase). Upon completion of this validation phase and according to obtained results, a randomized clinical trial will be conducted to compare the effects of the 5-day active 10Hz-tACS protocol with a 5-day sham-tACS protocol on brain dynamics modulation. This study will also compare intervention conditions on recovery of consciousness, cognition and function using short-term and long-term measurements.

Detailed description: Background: After a severe brain injury, a significant number of patients remain in a state of altered consciousness and the outcome remains difficult to prognosticate. There is a lack of evidence-based therapeutic interventions available for patients with disorders of consciousness; some evidence has been gathered for non-invasive brain stimulation, but these have targeted chronic patients. The objective of the validation phase will be to evaluate the differential feasibility parameters of conducting a 5-day tACS stimulation protocol in the ICU and the quality of data collection according to the various measurement modalities, to establish requirements to be used in a larger-scale study. This phase will also implicate a clinical pilot to confirm and assess the effect size of the primary outcome and sample size requirements for a clinical trial. Following completion, a clinical trial will be conducted to evaluate short-term and long-term neurophysiological effects of an optimized, multi-session tACS intervention in subacute brain-injured patients on their consciousness and functional recovery (as measured by complementary behavioural/functional scales), related brain oscillations and network dynamics.

Validation phase: In addition to conducting the following methods and design protocol, these measures will be acquired during the validation phase to assess the feasibility of this single-site study.

Recruitment rate and retention: Estimated number of patients in this condition in this ICU per year, estimated patient survival rates, number of eligible patients over a 12-month recruitment period; percentage of patients recruited, attrition, presence of competitive studies, etiologies and compliance of the families through experimental protocol and longitudinal assessment (12-month period).

Site demographics: Personnel's availabilities, Availability/accessibility of study coordinators, technicians, doctors and nurses; competency of the experimental team to conduct the experimental protocol.

Site infrastructure: Material storage (biological samples (centrifuge, freezer), Material obtention (Lidocaine obtention and renewal; EEG equipment), Data storage (clinically secure on-site servers).

Investigators' team requirements: Personnel requirements and the number of personnel required for the protocol's conductance.

Assessing the investigator's readiness in terms of standard care (eligibility decisions according to clinical profiles ), targeted study population and population recruited, and familiarity with the use of tools and technology.

Acceptability within the clinical care team's ecosystem: document pitfalls, difficulties and requirements to facilitate the clinical care team's adherence Quality of data collection: quality of EEG signal data in different clinical settings across main acquisition hospital sites; percentage of data acquisition completion; encountered data acquisition obstacles; assessment the estimated acquisition time for each measure and actual measuring times.

Methods/design:

The investigators will recruit brain-injured patients traumatic and non-traumatic etiologies (e.g., traumatic brain injury, anoxic brain injury, subarachnoid hemorrhage). Twelve patients will be recruited for the validation phase. The sample size estimation for the clinical trial based on a Student's t-test is 138 (2 groups of 69 patients) to reach a power of 80% to detect a statistically significant difference in the amplitude of alpha activity between active and sham groups, assuming a dropout/death rate of 20% and a significance level of 5%. These parameters are calculated according to a randomized, sham-controlled clinical trial comparing a 4-week tDCS protocol on patients with disorders of consciousness. The main outcome was a behavioral assessment, whereas this study's main outcome is neurophysiological, which is more sensitive to detect modulation effects. Additionally, this estimate will be readjusted according to the clinical pilot's results.

The study protocol will be activated once the medical team states clinical stability for the patients and withdrawal of continuous sedation has surpassed a minimum of 24 hours, without recovery of responsiveness.

Patients will participate in 7 consecutive experimental days including :

Day 0: Baseline measurements: Blood samples ( pharmacological agents dosage, the plasma expression of glial fibrillary acidic protein (GFAP) and isolation of exosomes derived from neurons (EDNs), astrocytes (EDAs) and microglia (EDMs)), Behavioral outcomes (Coma Recovery Scale-Revised (CRS-R), Glasgow Coma Scale (GCS) and Full Outline of Unresponsiveness (FOUR) Score) will be additionally measured for Unresponsive Wakefulness patients), pupillometry (photo motor reflex), and actigraph installation.

Days 1 to 5 (the following sequential procedure):

CRS-R/FOUR/GCS Pupillometry (PLR) 5-minute resting-state EEG 20-minute tACS/sham 5-minute resting-state EEG Pupillometry (PLR) CRS-R

5-minute resting-state 60-minute post-tACS condition/sham condition

5-minute resting-state 120-minute post-tACS condition/sham condition

Day 6:

CRS-R Pupillometry (PLR) 5-minute resting-state EEG

Day 7: After an interval of one-week post-5-day tACS/sham protocol, the following measurements will be acquired: CRS-R, Pupillometry (photo motor reflex), and 5-minute resting-state EEG. The actigraph will be withdrawn the during this same session.

At 3,6 and 12 months post-tACS, phone assessments will be conducted to measure long-term functional recovery using the following tools: Glasgow Outcome Scale- Extended, Disability Rating Scale, Functional Independence Measure and Burden Scale for Family Caregivers.

Eligibility criteria: Inclusion Criteria:

* Adults ≥ 18 years old; Glasgow Coma Scale score remaining ≤ 12 following a minimum of 24 hours after the withdrawal of continuous sedation (if applicable).
* The included brain injury etiologies for the Unresponsive Wakefulness Syndrome(UWS) or Minimally Conscious State (MCS) are traumatic and non-traumatic (e.g., traumatic brain injury, anoxic brain injury, subarachnoid hemorrhage).

Exclusion Criteria:

* Focal brain lesion(s) in the occipital and parietal lobes located at stimulation site
* Pre-existing severe neurological conditions/disorders involving cognitive deficits such as neurodegenerative diseases (ALS, dementia, Parkinson's), hereditary conditions (e.g. Huntington's Chorea), CNS disorders (previous moderate-severe CBT)
* History of epilepsy (patient with a seizure episode in response to non-exclusive active tACS intervention)
* Aneurysm clip(s), subdural brain electrodes, metallic brain, an implant, implantable neurostimulator
* Craniectomy with no bone flap
* Cervical collar limiting access to the occipital region
* Participation in a current (or previous) study that may have a confounding effect, as assessed by the research team.

To facilitate recruitment, upon medical consent family members of patients who present inclusion criteria before meeting the protocol activation criteria will be approached by the research team to get informed consent. The study will be activated once the medical team confirms clinical stability and withdrawal of continuous sedation for a minimum of 24 hours. The study protocol will not be activated if there is: Constant and intense agitation at the time of study activation, the presence of invasive neurological monitoring (ICP and/or PbtO2), GCS \> 12 after 24 hours of continuous sedation.

Primary outcomes:
measure: Single-site recruitment rates
timeFrame: 1 year
measure: Retention rates
timeFrame: over the 2-week course of the experimental protocol and at 3, 6 and 12 month time points
measure: Change in EEG spectral power of the alpha band activity
timeFrame: It will be measured over the 2-week course of the experimental protocol
measure: Change in Functional Connectivity based on EEG signal
timeFrame: It will be measured over the 2-week course of the experimental protocol
Secondary outcomes:
measure: Changes in Coma Recovery Scale Revised (CRS-R) score throughout the protocol.
timeFrame: It will be measured over the 2-week course of the experimental protocol
Other outcomes:
measure: Monitor non-invasively changes in the pupillary light reflex across the protocol
timeFrame: It will be measured over the 2-week course of the experimental protocol
measure: Monitor the recovery of wake-sleep cycles across the protocol
timeFrame: It will be measured over the 2-week course of the experimental protocol
measure: Characterize pharmacological agents, dosage of the plasma expression of the glial fibrillary acidic protein (GFAP) and to isolate exosomes derived from neurons (EDNs), astrocytes (EDAs) and microglia (EDMs).
timeFrame: Baseline measure (day 0)
measure: Longitudinal changes on global outcomes using GOSE and CPCs between conditions tACS and sham at 3, 6 and 12 months post-completion of the experimental protocol.
timeFrame: 1 year
measure: Longitudinal changes on Disability Rating Scale (DRS) and Functional Independence Measure (FIM) between conditions tACS and sham at 3, 6 and 12 months post-completion of the experimental protocol.
timeFrame: 1 year
measure: Changes in Subjective Burden Scale for Family Caregivers (BSFC-s) between conditions tACS and sham at 3, 6 and 12 months post-completion of the experimental protocol.
timeFrame: 1 year
measure: Changes in perceived health-related quality of life using EQ-5D-L5 between conditions tACS and sham at 3, 6 and 12 months post-completion of the experimental protocol.
timeFrame: 1 year
Locations:
Study officials:
References:
citation: Martens G, Lejeune N, O'Brien AT, Fregni F, Martial C, Wannez S, Laureys S, Thibaut A. Randomized controlled trial of home-based 4-week tDCS in chronic minimally conscious state. Brain Stimul. 2018 Sep-Oct;11(5):982-990. doi: 10.1016/j.brs.2018.04.021. Epub 2018 May 2.